A group of people looking at laboratory equipment.

Advancing Immunotherapy to Develop Novel and More Effective Treatment Strategies

Partner with us as we advance cancer immunotherapy frontiers

Get in contact
WHAT WE DO

Targeting Cancer with Innovative Allosteric Mechanisms

Developing a novel class of allosteric anti-PD-1 antibody that can further enhance conventional orthosteric anti-PD-1 therapies and work in tandem with other emerging immune checkpoint inhibitors.

Learn more
A group of red and white balls in the shape of DNA.
leadership

Our Team Is Our Strength

With deep expertise in immunology, virology, and oncology, our Leadership and Team of Experts is focused on solving complex challenges in oncology, infectious diseases, and allergy through innovative immune modulation.

Meet our team
A group of people in lab coats walking down a hallway.

Latest Scientific Insights

Discover some of our recent breakthroughs and research highlights.

View all publications
Journal of Experimental Medicine

Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway

2019

View authors
Frontiers in Immunology

A CD64/FcgammaRI-mediated mechanism hijacks PD-1 from PD-L1/2 interaction and enhances anti-PD-1 functional recovery of exhausted T cells

2023

View authors
Nature Microbiology

Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys

2022

View authors

Partner with Us

Backed by robust discovery-phase and early clinical funding, we now seek strategic investors and partners who share our vision to accelerate clinical development.

Partner with us

Patent-Backed Innovation

A robust worldwide intellectual property portfolio covering novel allosteric anti-PD-1 antibodies and combinations with classical anti-PD-1 antibodies, extending our market exclusivity, with patent protection for our lead asset secured until 2036.